INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Narrative review / 2007

Curcumin is safe up to 12 g/day in humans but exhibits poor bioavailability due to poor absorption, rapid metabolism, and rapid systemic elimination.

This review examines the bioavailability and pharmacologic properties of curcumin, a polyphenol derived from turmeric. Phase I clinical trials demonstrate that curcumin is safe even at high doses up to 12 g/day in humans, but it has poor bioavailability driven by poor absorption, rapid metabolism, and rapid systemic elimination. Approaches to enhance bioavailability include adjuvants like piperine, liposomal curcumin, nanoparticles, phospholipid complexes, and structural analogues such as EF-24. Despite low bioavailability, therapeutic efficacy has been documented against human diseases including cancer, cardiovascular diseases, diabetes, arthritis, neurological diseases, and Crohn's disease.

Study type
Narrative review
Who was studied
Humans in Phase I clinical trials
What was measured
Curcumin safety, bioavailability, and therapeutic efficacy

THE PAPER

Bioavailability of curcumin: problems and promises.

Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Mol Pharm, 2007.

PubMed 17999464 ↗DOI 10.1021/mp700113r ↗

Heart & arteriesDiabetes & blood sugarCancerGut & microbiomeBrain & moodOther health

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.